The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than ...

Citius Pharmaceuticals Inc (NASDAQ:CTXR) is a small-cap stock with a market capitalization of USD $26.49M. While investors primarily focus on the growth potential and competitive landscape of the ...

Citius Pharmaceuticals CTXR shares tumbled on Friday after the company announced a registered direct offering, a financing move that often pressures micro-cap biotech stocks due to dilution concerns.

Citius Pharmaceuticals Inc. (NASDAQ: CTXR) shares jumped 22.12% in after-hours trading to $1.27 on Tuesday, following the company’s fiscal year 2025 business update and the commercial launch of its ...

Citius Pharmaceuticals, Inc. CTXR announced that it has acquired the exclusive in-license rights of Dr. Reddy’s Laboratories RDY for E7777 (denileukin diftitox). The candidate is an improved ...

Fintel reports that on December 30, 2024, D. Boral Capital upgraded their outlook for Citius Pharmaceuticals (NasdaqCM:CTXR) from Hold to Buy. As of December 23, 2024, the average one-year price ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...